Dr. Hatou presents recent research progress in 2021 ISSCR VIRTUAL conference.
Tokyo (JUNE 21, 2021)-, Dr. Hatou, founder & CEO of Cellusion Inc., presents recent research progress in 2021 International Society for Stem Cell Research (ISSCR) VIRTUAL annual conference held online from June 21th to 26th.
The title of the presentation is that TRANSPLANTATION OF IPSC-DERIVED CORNEAL ENDOTHELIAL SUBSTITUTES IN A MONKEY BULLOUS KERATOPATHY MODEL.
With our cutting-edge cellular technology, Cellusion will accelerate our research program to deliver novel therapies for all bullous keratopathy patients.
Details on ISSCR, please see below. http://www.isscr.org/
<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.
Company ： Cellusion Inc.
CEO ： Shin Hatou, M.D., Ph.D.
Headquarter ：1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded ： January 2015
URL ： https://cellusion.jp/en/